{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T13:36:07Z","timestamp":1776605767845,"version":"3.51.2"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Adv Skin Wound Care"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Evidence to support available therapies for pyoderma gangrenosum (PG) is limited. Many patients do not respond to topical therapies such as tacrolimus or topical steroids. Currently favored oral systemic treatments (eg, cyclosporine and steroids) achieve complete remission in only 50% of patients and have unfavorable adverse effect profiles. There is a growing body of evidence to support biologic agents for the treatment of PG, but their exact role remains unclear. Here the authors present a patient with peristomal PG, the first reported case of PG responding to treatment with risankizumab, an anti-interleukin 23 monoclonal antibody. Risankizumab may represent an effective and relatively safe treatment for PG that merits additional exploration in prospective, controlled studies.<\/jats:p>","DOI":"10.1097\/01.asw.0000744324.59877.df","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T21:13:29Z","timestamp":1620854009000},"page":"327-329","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Peristomal Pyoderma Gangrenosum Responding to Risankizumab"],"prefix":"10.1097","volume":"34","author":[{"given":"Maximillian A.","family":"Weigelt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Kirsner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"1","key":"bib1-20250615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/gastro\/got013","article-title":"Diagnosis and management of parastomal pyoderma gangrenosum","volume":"1","year":"2013","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"3","key":"bib2-20250615","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7861\/clinmedicine.19-3-224","article-title":"Pyoderma gangrenosum\u2014a guide to diagnosis and management","volume":"19","year":"2019","journal-title":"Clin Med"},{"issue":"4","key":"bib3-20250615","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts","volume":"154","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"bib4-20250615","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/j.jaad.2015.05.010","article-title":"Peristomal pyoderma gangrenosum (PG): a simple hydrocolloid dressing technique to promote wound healing","volume":"73","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"bib5-20250615","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaad.2017.12.049","article-title":"Diagnosis and management of peristomal pyoderma gangrenosum: a systematic review","volume":"78","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"bib6-20250615","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying TH17 responses and autoimmunity","volume":"31","year":"2009","journal-title":"Immunity"},{"issue":"1","key":"bib7-20250615","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/bjd.13670","article-title":"The Treg\/TH17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum","volume":"173","year":"2015","journal-title":"Br J Dermatol"},{"issue":"4","key":"bib8-20250615","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/1060028019885836","article-title":"Risankizumab for the treatment of moderate to severe plaque psoriasis","volume":"54","year":"2020","journal-title":"Ann Pharmacother"}],"container-title":["Advances in Skin &amp; Wound Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.ASW.0000744324.59877.df","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T21:07:46Z","timestamp":1750021666000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.ASW.0000744324.59877.df"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/01.asw.0000744324.59877.df","relation":{},"ISSN":["1538-8654","1527-7941"],"issn-type":[{"value":"1538-8654","type":"electronic"},{"value":"1527-7941","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}